The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
NCCN guidelines focus on treatment options for patients with multiple myeloma: Recommendations highlight important updates specific to systemic therapy options for those with newly diagnosed or previously treated multiple myeloma
Open accessAbstract
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, recommendations highlight important updates specific to systemic therapy options for those with newly diagnosed or previously treated multiple myeloma. In addition, a persistent PSA level following radical prostatectomy for prostate cancer is associated with a worse prognosis, and outcomes show a reduction in treatment failure associated with dose‐escalated, hypofractionated radiation therapy for localized prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, prophylactic tocilizumab, not permitted in this study, is now recommended in guidelines and reduces the incidence and severity of cytokine release syndrome.34,35”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [35]
Citations
Cites
Avet‐Loiseau, H., Davies, F. E., Samur, M., Corre, J., D’Agostino, M., Kaiser, M., Raab, M. S., Weinhold, N., Gutierrez, N. C., Paiva, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01893 · Cited by 230
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Jr., Baljević, M., Baz, R., Campagnaro, E. L., Costello, C. L., D'Angelo, C. R., Derman, B. A., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0023 · Cited by 56
Research works printed but not linked: 1
- 10.1056/NEJMoa240902 · DOI
Cited by
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2514663 · Cited by 119
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Touzeau, C., Mina, R., Quach, H., Hungria, V., Bhutani, D., Chen, W., Kumar, S. S., Chaulagain, C. P., Dimopoulos, M. A., Bahlis, N. J., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603870 · Cited by 29
Revolutionizing 2L+ Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies
Mina, R., Doyle, M., & Nooka, A. K. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03715-z
Metadata
- Authors
- Nierengarten, M. B.
- Corresponding author
- Nierengarten, Mary Beth
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2025-08-31
- Volume
- 131
- Issue
- 17
- Pages
- e70014-e70014
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W4413867774
- Cited by
- 3
- References
- 2
- Citations by year
- 2026: 2 · 2025: 1
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- multiple myeloma, NCCN guidelines, systemic therapy, treatment options, newly diagnosed multiple myeloma, prostate cancer, prognosis, hypofractionated radiotherapy, dose escalation, localized prostate cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review